THE IMPORTANCE OF CANCER MONITORING AND TREATMENT

For cancer patients, post-treatment monitoring is crucial to detect minimal residual disease as well as signs of cancer recurrence, thereby making timely interventions. This can help an oncologist identify:
Routine tests used for screening and monitoring cancer treatment include immunohistochemistry index, CT scan, MRI, PET, endoscopy, scan, mammogram and X-ray, which are mainly imaging tests limited in their ability to detect very small traces of cancer in the blood when the tumour is very small or not visible to the naked eye (microscopic tumour).
If left untreated, residual cancer cells are highly likely to multiply and cause a recurrence.
K-TRACK TM helps detect minimal residuals of tumours after surgery.

VALUE OF K-TRACK TM IN CANCER MONITORING AND TREATMENT

K-TRACK TM is a non-invasive, custom-designed test that is based on each patient’s unique set of tumour mutations. It analyses the driver mutation of cancer cells to detect minimal DNA fragments from small residual tumours in the blood.
Detect minimal residual disease after radical surgery
Periodic minimal residual assessment via blood test
Investigate genetic mutations for targeted treatment of breast, lung, colorectal cancer

HOW IS K-TRACK TM DONE?

K-TRACK TM is a screening test which supports existing methods of monitoring recurrence. It also provides additional information for effective treatment direction.
Simultaneously analyse blood and tissue samples containing mutations specific to the patient’s tumour.
Personalise the test based on each patient’s unique set of tumour mutations.
Detect residual tumour DNA (ctDNA) after radical surgery and periodic monitoring over time.

WHY SHOULD YOU CHOOSE K-TRACK TM ?

WHO SHOULD UNDERGO K-TRACK TM AND WHEN?

Two to four weeks after radical surgery (1–2 weeks for liver cancer) to monitor minimal residual tumour.

Get routine checkups every 3–6 months for patients who have completed the treatment regimen. This helps monitor early recurrence.

Note:
K-TRACK TM is NOT USED for:

– Pre-surgery evaluation of neoadjuvant/adjuvant treatment.
– Patients with cancer recurrence.
– Pregnant patients.
– Patients with a history of bone marrow transplant or whole blood transfusion within the past three months.

After radical surgery, if:

• ctDNA (+): higher risk of your cancer returning —> Adjuvant monitoring.

• ctDNA (-): More likely to remain cancer-free —> RECURRENCE monitoring.

RETURNING TIME FOR K-TRACK TM RESULTS

At least 21–30 days
from first K-TRACKTM test
At least 7 days
for routine evaluation and follow-up tests
After 7–10 days
to receive genetic mutation results for targeted therapy (lung, breast, colorectal cancer)

SUPPORTING PROGRAM

Provide post-test counselling by medical geneticist/oncologist.

Support OncoGS – mutations for the target treatment of breast/lung/colorectal cancer results.

FAQs

GENE SOLUTIONS experts are listening to you!

GET MEDICAL CONSULTATION FROM DOCTORS

Tư vấn di truyền